Icure Pharmaceutical Incorporation아이큐어
175250 · KOSDAQ · ₩175250 · 아이큐어
- Market cap
- ₩89B
- Enterprise value
- ₩105B
- P/E
- —
- P/B
- 3.2×
- Dividend yield
- 0.0%
- ROE
- −71.2%
- Net margin
- −18.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−56.5% from the high
₩1,370Today: ₩1,380 – ₩1,466₩3,300
Returns
- 1W−3.2%
- 1M−14.5%
- 3M−49.9%
- 6M−49.9%
- YTD−49.9%
- 1Y−49.9%
- Volume today
- 50,816
- 0.5× the 20-day average
- Traded today
- ₩72M
- Listed shares
- 61,736,317
- EPS (12 months)
- −₩324
- Earnings yield −22.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 32 of 100 (50 is a normal day for this stock).
- MomentumWeak-15.5% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Icure Pharmaceutical Incorporation stock overview
Icure Pharmaceutical Incorporation (아이큐어, KRX: 175250) is listed on KOSDAQ, in the Chemicals sector. The company, founded in May 2000, develops and manufactures patch-type drugs based on its transdermal drug delivery system (TDDS) technology and provides OEM and ODM cosmetics manufacturing, including basic skincare products and mask packs. Its shares closed at ₩1,437 on Oct 28, 2026, up 0.49% on the day, giving it a market value of ₩89B.
Key facts
- Market cap
- ₩89B
- Sector
- Chemicals
- Latest price change
- +0.49%
- As of
- Oct 28, 2026
- Main business
- The company, founded in May 2000, develops and manufactures patch-type drugs based on its transdermal drug delivery system (TDDS) technology and provides OEM and ODM cosmetics manufacturing, including basic skincare products and mask packs.
Quick answers about Icure Pharmaceutical Incorporation
- What does Icure Pharmaceutical Incorporation do?
- The company, founded in May 2000, develops and manufactures patch-type drugs based on its transdermal drug delivery system (TDDS) technology and provides OEM and ODM cosmetics manufacturing, including basic skincare products and mask packs. Its pharmaceutical products include plasters and patches, and its main customers are large pharmaceutical and cosmetics manufacturers, with headquarters and research facilities in Seoul and a manufacturing plant in Wanju-gun, Jeollabuk-do. It has licensed and supplied its donepezil patch internationally through agreements with partners such as Menarini and Celltrion.
- What is the market cap of Icure Pharmaceutical Incorporation?
- The market capitalisation of Icure Pharmaceutical Incorporation was ₩89B at the close on Oct 28, 2026.
- Who are the largest shareholders of Icure Pharmaceutical Incorporation?
- According to the latest official filings, the largest reported holders are Solum Cosmetic (40.07%, as of Oct 7, 2026); Choi Young-kwon (15.34%, as of Mar 12, 2025); Hyun Yong-su (0.73%, as of Sep 30, 2026).
- When is the next earnings report from Icure Pharmaceutical Incorporation?
- Korean companies rarely announce results dates in advance. Based on when Icure Pharmaceutical Incorporation filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Icure Pharmaceutical Incorporation?
- Yes. The National Pension Service held 0.20% of Icure Pharmaceutical Incorporation shares as of Dec 31, 2018.
Company profile
The company, founded in May 2000, develops and manufactures patch-type drugs based on its transdermal drug delivery system (TDDS) technology and provides OEM and ODM cosmetics manufacturing, including basic skincare products and mask packs. Its pharmaceutical products include plasters and patches, and its main customers are large pharmaceutical and cosmetics manufacturers, with headquarters and research facilities in Seoul and a manufacturing plant in Wanju-gun, Jeollabuk-do. It has licensed and supplied its donepezil patch internationally through agreements with partners such as Menarini and Celltrion.
Written by AI from the company's latest annual report.
- Korean name
- 아이큐어
- Sector
- Chemicals
- Themes
- Pharmaceuticals
- CEO
- 이영석
- Founded
- May 2000
- Listed
- Jul 2018
- Listed shares
- 61,736,317
- Fiscal year ends
- Month 12
- Website
- icure.co.kr
Similar companies
- LG Chem051910 · ₩17T₩236,000+3.28%
- Hanwha Solutions009830 · ₩6T₩26,700+3.29%
- Hanwha000880 · ₩5T₩94,000+1.40%
- SKC011790 · ₩4.1T₩82,900−0.36%
- KCC002380 · ₩3.4T₩397,000+5.31%
- Kumho Petro Chemical011780 · ₩2.7T₩106,800+0.75%
- Soulbrain357780 · ₩2.5T₩318,000+3.58%
- Hansol Chemical014680 · ₩2.4T₩219,500+7.60%
Recent filings
See all- Amended: Half-year report (Jun 2026)Oct 20, 2026
- Amended: Half-year report (Jun 2026)Oct 20, 2026
- Amended: 5%+ holding reportOct 7, 2026
- 5%+ holding reportOct 7, 2026
- Insider shareholding reportSep 30, 2026
Titles in Korean until English translations are added.
Also known as: Icure Pharmaceutical Incorporation / 아이큐어 / 175250 / KRX:175250
Source: KRX statistical information